0000000000256223

AUTHOR

Frédéric Bourdain

showing 2 related works from this author

Health-Related Quality of Life Is Severely Affected in Primary Orthostatic Tremor

2018

International audience; Background: Primary orthostatic tremor (POT) is a movement disorder characterized by unsteadiness upon standing still due to a tremor affecting the legs. It is a gradually progressive condition with limited treatment options. Impairments in health-related quality of life (HQoL) seem to far exceed the physical disability associated with the condition.Methods: A multi-center, mixed-methodology study was undertaken to investigate 40 consecutive patients presenting with POT to four movement disorder centers in France. HQoL was investigated using eight quantitative scales and a qualitative study which employed semi-structured interviews. Qualitative data were analyzed wit…

medicine.medical_specialtyPhysical disabilityQualitative propertyprogressiveFear of fallinglcsh:RC346-429Grounded theory03 medical and health sciences0302 clinical medicineQuality of life (healthcare)Physical medicine and rehabilitationMedicine030212 general & internal medicinelcsh:Neurology. Diseases of the nervous systemOriginal Researchbusiness.industryMultimethodology3. Good healthprimary orthostatic tremorhealth-related quality of lifeNeurology[ SDV.NEU ] Life Sciences [q-bio]/Neurons and Cognition [q-bio.NC][SDV.NEU]Life Sciences [q-bio]/Neurons and Cognition [q-bio.NC]movement disorderNeurology (clinical)Thematic analysismedicine.symptombusinessmixed-method methodology030217 neurology & neurosurgeryNeuroscienceQualitative research
researchProduct

Benefit of Targeting a LDL (Low-Density Lipoprotein) Cholesterol \textless70 mg/dL During 5 Years After Ischemic Stroke

2020

Background and Purpose— The TST trial (Treat Stroke to Target) evaluated the benefit of targeting a LDL (low-density lipoprotein) cholesterol of <70 mg/dL to reduce the risk of cardiovascular events in 2860 patients with ischemic stroke with atherosclerotic stenosis of cerebral vasculature or aortic arch plaque >4 mm, in a French and Korean population. The follow-up lasted a median of 5.3 years in French patients (similar to the median follow-up time in the SPARCL trial [Stroke Prevention by Aggressive Reduction in Cholesterol Level]) and 2.0 years in Korean patients. Exposure duration to statin is a well-known driver for cardiovascular risk reduction. We report here the TST results …

Malemedicine.medical_specialtyStatinTime Factorsmedicine.drug_class[SDV]Life Sciences [q-bio]Brain IschemiaLDLchemistry.chemical_compoundDrug Delivery SystemsEzetimibeInternal medicinemedicineClinical endpointHumansangiographyMyocardial infarctionStrokeAgedAdvanced and Specialized NursingCerebral infarctionCholesterolbusiness.industryAnticholesteremic Agentsinformed consentcholesterolCholesterol LDLMiddle Agedmedicine.diseaseEzetimibestroke[SDV] Life Sciences [q-bio]aortachemistryNumber needed to treatCardiologyFemaleNeurology (clinical)Cardiology and Cardiovascular Medicinebusinessmedicine.drug
researchProduct